nach oben

Erschienen in:

01.01.2022 | News item

Atypical haemolytic reactions after gemtuzumab ozogamicin

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Five cases of intravascular haemolytic reactions (haemolysis) have been reported internationally after treatment with gemtuzumab ozogamicin [Mylotarg], reports Health Canada. The cases were associated with atypical laboratory reactions including high plasma haemoglobin and normal to high plasma haptoglobin, which could be incorrectly interpreted as in vitro haemolysis and therefore delay diagnosis and treatment of the adverse reactions. …

Health Canada. Atypical hemolytic reactions following exposure to gemtuzumab ozogamicin Health Product InfoWatch : 3-4, Dec 2021. Available from: URL: https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/medeffect-canada/health-product-infowatch/december-2021/december-2021.pdf

Titel: Atypical haemolytic reactions after gemtuzumab ozogamicin
Publikationsdatum: 01.01.2022
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-08343-9

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Analgesics/methylprednisolone

Multiple drugs

AZD-1222

Atorvastatin

Methotrexate

Doxycycline/fusidic acid/tofacitinib